Literature DB >> 8298

[Treatment of hypertrophic obstructive cardiomyopathy with verapamil, a calcium antagonist (author's transl)].

M Kaltenbach, R Hopf, M Keller.   

Abstract

Cardiac catheterisation with pressure measurements, left-ventricular cine-angiography and selective coronary angiography confirmed the diagnosis of hypertrophic obstructive cardiomyopathy in 20 patients. After a mean observation period of 20 months during which most of them were treated with beta-blockers, verapamil, 480 mg by mouth, was given for an average of 12 months. There was an impressive improvement in symptoms, compared with the state under beta-blocker treatment. There was a significant reduction in the ECG signs of left-ventricular hypertrophy and of the radiologically measured heart volume. Treatment of this condition with verapamil appeared to be superior to that with beta-blockers.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 8298     DOI: 10.1055/s-0028-1104257

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  9 in total

Review 1.  Nonobstructive and obstructive hypertrophic cardiomyopathies.

Authors:  J Ross; R Shabetai; G Curtis; R L Engler; D L Costello; M M LeWinter; A D Johnson; C B Higgins; G Gregoratos; J R Utley; R Shabetai
Journal:  West J Med       Date:  1979-04

2.  Treatment of hypertrophic obstructive cardiomyopathy with verapamil.

Authors:  M Kaltenbach; R Hopf; G Kober; W D Bussmann; M Keller; Y Petersen
Journal:  Br Heart J       Date:  1979-07

3.  Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart.

Authors:  D R Ferry; H Glossmann; A J Kaumann
Journal:  Br J Pharmacol       Date:  1985-04       Impact factor: 8.739

4.  Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.

Authors:  M Eichelbaum; A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Laboratory and initial clinical studies of nifedipine, a calcium antagonist for improved myocardial preservation.

Authors:  R E Clark; I Y Christlieb; T B Ferguson; C S Weldon; J P Marbarger; B E Sobel; R Roberts; P D Henry; P A Ludbrook; D Biello; B K Clark
Journal:  Ann Surg       Date:  1981-06       Impact factor: 12.969

Review 6.  Role of calcium antagonists in cardiovascular therapy.

Authors:  H Dargie; E Rowland; D Krikler
Journal:  Br Heart J       Date:  1981-07

7.  Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets.

Authors:  M Eichelbaum; H J Dengler; A Somogyi; G E von Unruh
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

8.  Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole.

Authors:  J K Gwathmey; S E Warren; G M Briggs; L Copelas; M D Feldman; P J Phillips; M Callahan; F J Schoen; W Grossman; J P Morgan
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

Review 9.  Mass-Spectrometry-Based Functional Proteomic and Phosphoproteomic Technologies and Their Application for Analyzing Ex Vivo and In Vitro Models of Hypertrophic Cardiomyopathy.

Authors:  Jarrod Moore; Andrew Emili
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.